Shares of Biogen Inc. BIIB advanced 2.03% to $187.57 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising 0.11% to ...
The US Food and Drug Administration has approved a higher-dose version of Spinraza, a key therapy from Biogen Inc ...
Biogen Inc. BIIB shares are up on Monday following the FDA’s approval of a new high-dose regimen for Spinraza (nusinersen), a ...
(Nasdaq: BIIB) today announced that the High Dose Regimen of SPINRAZA ® (nusinersen), which is comprised of 50 mg/5 mL and 28 mg/5 mL doses, was approved by the U.S. Food and Drug Administration (FDA) ...
In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving clea ...
US regulators have approved a high-dose version of Biogen Inc.’s drug for a rare muscle disorder, giving the company a boost as it competes with a gene therapy from Novartis AG.
Alteogen Inc. (KOSDAQ: 196170) announced today that it has entered into an exclusive license agreement with Biogen Inc. for the development and commercialization of subcutaneous (SC) formulations of ...
The bond market trimmed what’s expected to be its worst monthly selloff since 2024 as Powell said longer-term inflation ...
CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company d ...
Scientists at the University of California, San Diego, have identified a blood signal that could forecast dementia risk decades before symptoms begin. Their study, recently published in JAMA Network ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results